Literature DB >> 24927973

Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention.

Mitsuru Abe1, Takeshi Morimoto2, Masaharu Akao3, Yutaka Furukawa4, Yoshihisa Nakagawa5, Satoshi Shizuta6, Natsuhiko Ehara4, Ryoji Taniguchi7, Takahiro Doi6, Kei Nishiyama8, Neiko Ozasa6, Naritatsu Saito6, Kozo Hoshino9, Hirokazu Mitsuoka10, Masanao Toma7, Toshihiro Tamura5, Yoshisumi Haruna11, Toru Kita4, Takeshi Kimura6.   

Abstract

There is little information on the effect of contrast-induced nephropathy (CIN) on long-term mortality after percutaneous coronary intervention in patients with or without chronic kidney disease (CKD). Of 4,371 patients who had paired serum creatinine (SCr) measurements before and after percutaneous coronary intervention and were discharged alive in the Coronary REvascularization Demonstrating Outcome Study in Kyoto registry, the incidence of CIN (an increase in SCr of ≥0.5 mg/dl from the baseline) was 5% in our study cohort. The rate of CIN in patients with CKD was 11%, although it was 2% without CKD (p <0.0001). During a median follow-up of 42.3 months after discharge, 374 patients (8.6%) died. After adjustment for prespecified confounders, CIN was significantly correlated with long-term mortality in the entire cohort (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.62 to 2.29, p <0.0001) and in patients with CKD (HR 2.62, 95% CI 1.91 to 3.57, p <0.0001) but not in patients without CKD (HR 1.23, 95% CI 0.47 to 2.62, p = 0.6). Sensitivity analyses confirmed these results using the criteria defined as elevations of the SCr by ≥25% and 0.3 mg/dl from the baseline, respectively. In conclusion, CIN was significantly correlated with long-term mortality in patients with CKD but not in those without CKD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927973     DOI: 10.1016/j.amjcard.2014.05.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

2.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Clin Exp Nephrol       Date:  2020-01       Impact factor: 2.801

3.  Predictors and Outcomes of Postcontrast Acute Kidney Injury after Endovascular Renal Artery Intervention.

Authors:  Edwin A Takahashi; David F Kallmes; Chad J Fleming; Robert J McDonald; Michael A McKusick; Haraldur Bjarnason; William S Harmsen; Sanjay Misra
Journal:  J Vasc Interv Radiol       Date:  2017-09-22       Impact factor: 3.464

4.  The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.

Authors:  Xingji Lian; Wenfei He; Huimin Zhan; Jiyan Chen; Ning Tan; Pengcheng He; Yuanhui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

5.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Jpn J Radiol       Date:  2020-01       Impact factor: 2.374

Review 6.  [Contrast medium-induced acute kidney injury-Consensus paper of the working group "Heart and Kidney" of the German Cardiac Society and the German Society of Nephrology].

Authors:  J Latus; V Schwenger; G Schlieper; H Reinecke; J Hoyer; P B Persson; B A Remppis; F Mahfoud
Journal:  Internist (Berl)       Date:  2020-12-21       Impact factor: 0.743

7.  Coronary artery calcification scores improve contrast-induced nephropathy risk assessment in chronic kidney disease patients.

Authors:  Naohiro Osugi; Susumu Suzuki; Yohei Shibata; Yosuke Tatami; Shingo Harata; Tomoyuki Ota; Mutsuharu Hayashi; Yoshinari Yasuda; Hideki Ishii; Atsuya Shimizu; Toyoaki Murohara
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

8.  Kidney Injury Molecule-1 Is Associated with Contrast-Induced Nephropathy in Elderly Patients with Non-STEMI.

Authors:  Mustafa Ahmet Huyut
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

9.  Contrast-induced nephropathy in patients with chronic kidney disease and peripheral arterial disease.

Authors:  Christian Kroneberger; Christian N Enzweiler; Andre Schmidt-Lucke; Ralph-Ingo Rückert; Ulf Teichgräber; Tobias Franiel
Journal:  Acta Radiol Open       Date:  2015-06-24

10.  Magnitude and associated factors of contrast induced nephropathy among patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania - a cross-sectional study.

Authors:  Pilly Chillo; Ng Wigulu Malaja; Peter Kisenge
Journal:  Pan Afr Med J       Date:  2021-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.